TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 1606996
Drug: Oxazepam 20
Normalized name: oxazepam 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oxazepam 20 mg
Study: 1606996
Drug: Oxazepam 40
Normalized name: Oxazepam
DrugBank: Oxazepam acetate (DB14672)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oxazepam 40 mg
Study: 8748394
Drug: Oxazepam (both
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oxazepam (both doses)
Study: 20511163
Drug: Weight-based, dose-adjusted
Approvals — FDA: no, EMA: no, PMDA: no
Description: Weight-based, dose-adjusted filgrastim beginning on day 1 (arm B)
Study: 21346616
Drug: Quetiapine 600
Approvals — FDA: no, EMA: no, PMDA: no
Description: Quetiapine 600 mg/d
Study: 17110817
Drug: Quetiapine 300
Normalized name: quetiapine 300 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Quetiapine 300 mg/d
Study: 19956459
Drug: Quetiapine (both
Approvals — FDA: no, EMA: no, PMDA: no
Description: Quetiapine (both doses)
Study: 23499726
Drug: Octreotide monotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Octreotide monotherapy (octreotide 40 mg every 4 weeks)
Study: 18095028
Drug: Topical sucralfate
Normalized name: Sucralfate
DrugBank: Sucralfate (DB00364)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Topical sucralfate cream
Study: 8616014
Drug: All three
Normalized name: three-lobe sage extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: All three treatment arms (FLAC + PIXY321, FLAC + GM‐CSF, FLAC without cytokine)
Study: 26836730
Drug: Acetazolamide (500-1000
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acetazolamide (500-1000 mg, twice daily)
Study: 30791951
Drug: Daily breakfast
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily breakfast consumption
Study: 17215188
Drug: NaFeEDTA (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: NaFeEDTA (20 mg Fe/kg)
Study: 17215188
Drug: FeSO4 (30
Approvals — FDA: no, EMA: no, PMDA: no
Description: FeSO4 (30 mg Fe/kg)
Study: 11730828
Drug: Combined hormone
Normalized name: Parathyroid Hormone
DrugBank: Parathyroid hormone (DB05829)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Combined hormone replacement therapy (2 mg of estradiol combined with 1 mg of norethisterone acetate daily)
Study: 9143862
Drug: Celiprolol (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Celiprolol (2 times 0.5 mg.kg‐1)
Study: 18626783
Drug: Intraurethral 30
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intraurethral 30 ml of 2% lidocaine jelly
Study: 18626783
Drug: Intraurethral 30
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intraurethral 30 ml of neutral jelly
Study: 16230677
Drug: Concurrent chemoradiotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Concurrent chemoradiotherapy (CCRT) with oxaliplatin 70 mg/m2 weekly for six doses
Study: 24119807
Drug: Insulin glargine
Normalized name: Insulin Glargine
DrugBank: Insulin glargine (DB00047)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Insulin glargine (L)
Study: 19411792
Drug: Health education
Normalized name: Healthy Mama
Approvals — FDA: no, EMA: no, PMDA: no
Description: Health education program using problem-based learning, 5 weekly sessions, 100-120 min/session
Study: 18060072
Drug: Co-administration of
Approvals — FDA: no, EMA: no, PMDA: no
Description: Co-administration of UK-39 and AMA49-C1 loaded virosomes
Study: 9059563
Drug: Pamidronate therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pamidronate therapy (150 mg/day) for 3 years
Study: 9059563
Drug: Discontinuation of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Discontinuation of pamidronate therapy for 12 months
Study: 9059563
Drug: Post-discontinuation BMD
Normalized name: post oak pollen extract
DrugBank: Quercus stellata pollen (DB10888)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Post-discontinuation BMD measurement after 1 year
Study: 8880076
Drug: Moclobemide 300
Normalized name: moclobemide 300 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Moclobemide 300 mg
Study: 9663810
Drug: Moclobemide 450
Normalized name: moclobemide
DrugBank: Moclobemide (DB01171)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Moclobemide 450 mg
Study: 11195257
Drug: Moclobemide 600
Normalized name: moclobemide
DrugBank: Moclobemide (DB01171)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Moclobemide 600 mg
Study: 4054700
Drug: L-dopa (500
Approvals — FDA: no, EMA: no, PMDA: no
Description: L-dopa (500 mg)
Study: 4054700
Drug: L-dopa (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: L-dopa (100 mg) plus carbidopa (35 mg) after pretreatment with carbidopa (50 mg every six hours for four doses)
Study: 18398147
Drug: Toremifene (80
Approvals — FDA: no, EMA: no, PMDA: no
Description: Toremifene (80 mg/d)
Study: 1543819
Drug: Lansoprazole 30
Normalized name: lansoprazole 30 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lansoprazole 30 mg am
Study: 1782306
Drug: Famotidine 40
Normalized name: famotidine 40 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Famotidine 40 mg nocte
Study: 31384310
Drug: Glibenclamide 5
Normalized name: glibenclamide 5 MG Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Glibenclamide 5 mg/day
Study: 27028957
Drug: Somatostatin analog
Normalized name: Somatostatin analog
Approvals — FDA: no, EMA: no, PMDA: no
Description: Somatostatin analog (SSA) therapy
Study: 27028957
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (no SSA therapy)
Study: 23681906
Drug: Inhaled dual
Normalized name: Tums Dual Action
DrugBank: Alginic acid (DB13518)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhaled dual release ciprofloxacin (DRCFI)
Study: 20492710
Drug: Gold+Lutein (Wyeth
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gold+Lutein (Wyeth S‐26 Gold fortified with lutein at 200 mcg/l)
Study: 10849523
Drug: Roquinimex 0.2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Roquinimex 0.2 mg/kg body weight, twice weekly for 2 years
Study: 9203426
Drug: Higher-dose amphotericin
Normalized name: amphotericin
DrugBank: Amphotericin B (DB00681)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Higher-dose amphotericin B (0.7 mg/kg/day) plus flucytosine (100 mg/kg/day) for two weeks
Study: 9203426
Drug: Higher-dose amphotericin
Normalized name: amphotericin
DrugBank: Amphotericin B (DB00681)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Higher-dose amphotericin B (0.7 mg/kg/day) alone
Study: 9203426
Drug: Fluconazole (400
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fluconazole (400 mg/day) for eight weeks
Study: 20845628
Drug: Ketamine 0.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ketamine 0.5 mg kg-1 intravenously 20 min before completion of surgery
Study: 19014842
Drug: Amoxicillin/clavulanate (80-90
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amoxicillin/clavulanate (80-90 mg/kg amoxicillin daily) for 14 days
Study: 12855319
Drug: Dexketoprofen trometamol
Normalized name: Dexketoprofen trometamol
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dexketoprofen trometamol 25 mg q.i.d.
Study: 25363203
Drug: CTG +
Normalized name: somatropin
DrugBank: Somatotropin (DB00052)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: CTG + L (Connective Tissue Graft with Low-Level Laser Therapy)
Study: 25363203
Drug: Both groups
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Both groups (CTG and CTG + L)
Study: 23458226
Drug: Rivaroxaban 10
Normalized name: rivaroxaban 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rivaroxaban 10 mg tablet under fed conditions
Study: 23458226
Drug: Rivaroxaban 15
Normalized name: rivaroxaban 15 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rivaroxaban 15 mg tablet under fed conditions
Study: 23458226
Drug: Rivaroxaban 20
Normalized name: rivaroxaban 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rivaroxaban 20 mg tablet under fed conditions
Study: 23458226
Drug: Rivaroxaban 15
Normalized name: rivaroxaban 15 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rivaroxaban 15 mg tablet under fasting conditions
Study: 23458226
Drug: Rivaroxaban 20
Normalized name: rivaroxaban 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rivaroxaban 20 mg tablet under fasting conditions
Study: 23458226
Drug: Rivaroxaban 10
Normalized name: rivaroxaban 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rivaroxaban 10 mg oral suspension under fasting conditions
Study: 23458226
Drug: Rivaroxaban 20
Normalized name: rivaroxaban 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rivaroxaban 20 mg oral suspension under fasting and fed conditions
Study: 20112484
Drug: Yiqi Bushen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Yiqi Bushen Koufuye combined with chemotherapy
Study: 3524465
Drug: Chemotherapy (control
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chemotherapy (control group)
Study: 16675812
Drug: Rectal quinine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rectal quinine (20 mg/kg diluted to 30 mg/ml in water solution)
Study: 16675812
Drug: Intramuscular quinine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intramuscular quinine (12.5 mg/kg)
Study: 15065610
Drug: Fluticasone propionate
Normalized name: Fluticasone Propionate
DrugBank: Fluticasone propionate (DB00588)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Fluticasone propionate 88 microg twice daily
Study: 7604802
Drug: Fluvastatin 20
Normalized name: fluvastatin 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fluvastatin 20 mg/day plus cholestyramine 4 g/day
Study: 7604802
Drug: Fluvastatin 20
Normalized name: fluvastatin 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fluvastatin 20 mg/day plus cholestyramine 8 g/day
Study: 7604802
Drug: Fluvastatin plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fluvastatin plus cholestyramine (all doses)
Study: 345423
Drug: 1 g
Normalized name: Molds 1 g
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 g of cephradine orally twice daily (b.i.d.)
Study: 345423
Drug: 500 mg
Normalized name: bran 500 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 500 mg of cephradine given 4 times a day (q.i.d.)
Study: 24615239
Drug: Caffeine-containing energy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Caffeine-containing energy drink (3 mg of caffeine/kg)
Study: 17468493
Drug: Group 1:
Approvals — FDA: no, EMA: no, PMDA: no
Description: Group 1: BIS 45(5), remifentanil 1 ng ml(‐1)
Study: 17468493
Drug: Group 3:
Approvals — FDA: no, EMA: no, PMDA: no
Description: Group 3: BIS 45(5), remifentanil 4 ng ml(‐1)
Study: 12469979
Drug: 200 mg
Normalized name: RNA 200 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 200 mg modified release capsule of mebeverine
Study: 12469979
Drug: 135 mg
Normalized name: cocaine 135 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 135 mg plain tablet of mebeverine
Study: 9306300
Drug: Dopamine receptor
Normalized name: Dopamine receptor
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dopamine receptor antagonists (haloperidol or fluphenazine)
Study: 3537635
Drug: guanfacine (0.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: guanfacine (0.5 mg/day)
Study: 30135020
Drug: Dose modification
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dose modification (adjustment or treatment delay)
Study: 30135020
Drug: Granulocyte colony
Normalized name: Granulocyte colony stimulating factor
DrugBank: Filgrastim (DB00099)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Granulocyte colony stimulating factor (G‐CSF) use in dose-modified patients
Study: 30135020
Drug: No dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: No dose modification (referent group)
Study: 25460150
Drug: Immediate release
Normalized name: Namenda, immediate release oral kit
Approvals — FDA: no, EMA: no, PMDA: no
Description: Immediate release tablet Sirdalud® (control).
Study: 20172704
Drug: Ipratropium bromide/albuterol
Normalized name: ipratropium bromide/albuterol sulfate 0.5 mg-2.5 mg/2.5 mL INHALATION VIAL, NEBULIZER (ML)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ipratropium bromide/albuterol Respimat inhaler (20/100mcg)
Study: 8669601
Drug: Cisapride 20
Normalized name: cisapride 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cisapride 20 mg plus diazepam 10 mg
Study: 28884737
Drug: Acupuncture therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acupuncture therapy (reflexotherapy) combined with pharmacotherapy and psychologist's recommendations
Study: 28884737
Drug: Medication therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Medication therapy and psychotherapy without acupuncture
Study: 25886327
Drug: Group FPM
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Group FPM (IV fortwin 0.3 mg/kg over 1 min + IV midazolam 0.04 mg/kg + IV phenergan 12.5 mg)
Study: 25886327
Drug: Group KM
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Group KM (IV ketamine 0.3 mg/kg over 1 min + IV midazolam 0.04 mg/kg)
Study: 19765321
Drug: 0.12% chlorhexidine
Normalized name: CHLORHEXIDINE GLUCONATE 1.2 [iU] in 1 mL BUCCAL MOUTHWASH [0.12% Chlorhexidine Gluconate Oral Rinse]
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.12% chlorhexidine gluconate applied once or twice a day
Study: 17534818
Drug: Topical betaxolol
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical betaxolol HCl 0.25% suspension
Study: 17534818
Drug: Topical betaxolol
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical betaxolol HCl 0.50% solution
Study: 9725482
Drug: Two suppositories
Normalized name: potassium bitartrate / sodium bicarbonate Rectal Suppository [Ceo-Two]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Two suppositories of 500 mg
Study: 9725482
Drug: Two tablets
Approvals — FDA: no, EMA: no, PMDA: no
Description: Two tablets of 500 mg
Study: 31555824
Drug: PfSPZ vaccine
Normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
Approvals — FDA: no, EMA: no, PMDA: no
Description: PfSPZ vaccine (doses: 1.35 × 10^5, 2.7 × 10^5, 4.5 × 10^5, 9.0 × 10^5, and 1.8 × 10^6) administered by direct venous inoculation (DVI)
Study: 31555824
Drug: PfSPZ vaccine
Normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
Approvals — FDA: no, EMA: no, PMDA: no
Description: PfSPZ vaccine (doses: 9.0 × 10^5 and 1.8 × 10^6)
Study: 28391437
Drug: Intravenous iron
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous iron (IV ferric gluconate 125 mg weekly for 8 weeks)
Study: 28391437
Drug: Oral sucrosomial
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral sucrosomial iron (30 mg daily for 8 weeks)
Study: 28391437
Drug: Intravenous iron
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous iron (IV ferric gluconate)
Study: 24186595
Drug: Exenatide 10
Normalized name: EXENATIDE 10MCG/DOSE 2.4ML 60D PEN
Approvals — FDA: no, EMA: no, PMDA: no
Description: Exenatide 10 μg BID (n = 40)
Study: 24186595
Drug: Insulin glargine
Normalized name: Insulin Glargine
DrugBank: Insulin glargine (DB00047)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Insulin glargine once daily (n = 40)
Study: 21990399
Drug: Patients with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients with residual disease after chemotherapy
Study: 18434722
Drug: Buffered phosphate
Normalized name: PHOSPHATE BUFFERS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Buffered phosphate solution (placebo control, n = 12)
Study: 17075117
Drug: Docetaxel 75
Normalized name: Docetaxel
DrugBank: Docetaxel (DB01248)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Docetaxel 75 mg/m2 and cisplatin 75 mg/m2 plus fluorouracil 750 mg/m2/d (DCF)
Study: 17075117
Drug: Cisplatin 100
Normalized name: CISPLATIN 100MG/VIL (PF) INJ
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cisplatin 100 mg/m2 plus fluorouracil 1,000 mg/m2/d (CF)
Study: 10901181
Drug: Epoetin alfa
Normalized name: epoetin alfa
DrugBank: Erythropoietin (DB00016)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Epoetin alfa (doses slowly escalating to achieve hematocrit of 42+/‐3%)
Study: 8837186
Drug: Single-shot spinal
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single-shot spinal anesthesia with 1% hyperbaric bupivacaine (0.27 mg/kg)
Study: 8837186
Drug: Incremental 5-mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: Incremental 5-mg bolus of 1% hyperbaric bupivacaine via a subarachnoid 32-gauge microcatheter every 10 minutes
Study: 1570381
Drug: 0.2 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.2 mg/kg oral diazepam
Study: 26616644
Drug: Oral chloral
Normalized name: Chloral Hydrate
DrugBank: Chloral hydrate (DB01563)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral chloral hydrate 70 mg · kg(‐1)
Study: 25238873
Drug: 4 weekly
Normalized name: TOBI Podhaler Kit, 4 Weekly Packs, each including 56 capsules (7 Blister Cards of 8 Capsules)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4 weekly regular early specialist symptom control care
Study: 21890793
Drug: Usual community
Approvals — FDA: no, EMA: no, PMDA: no
Description: Usual community treatment
Study: 21890793
Drug: Cumulative stimulant
Normalized name: Staphylococcus simulans
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cumulative stimulant exposure
Study: 30618445
Drug: Two-dose sulphadoxine-pyrimethamine
Normalized name: pyrimethamine / sulfadoxine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Two-dose sulphadoxine-pyrimethamine (SP)
Study: 7864420
Drug: 0.15 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.15 mg/kg of mivacurium after 1.0 mg/kg of succinylcholine
Study: 7864420
Drug: 0.15 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.15 mg/kg of mivacurium without succinylcholine
Study: 7262517
Drug: Slow duodenal
Normalized name: Slow Sodium
Approvals — FDA: no, EMA: no, PMDA: no
Description: Slow duodenal perfusion rate of [14C]PEG in saline (0.25 ml/min)
Study: 7262517
Drug: Fast duodenal
Normalized name: Fast Freeze
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fast duodenal perfusion rate (3.0 ml/min)
Study: 28110628
Drug: Sublingual glyceryl
Normalized name: glyceryl
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sublingual glyceryl trinitrate (800 µg)
Study: 9282968
Drug: Aflurax (1200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aflurax (1200 mg, two tablets four times daily for 4 weeks)
Study: 9282968
Drug: Placebo (two
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (two tablets four times daily for 4 weeks)
Study: 2433098
Drug: Oral hydromorphone
Normalized name: hydromorphone Oral Solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral hydromorphone hydrochloride 2 mg
Study: 28679555
Drug: Juice supplemented
Normalized name: tamarind juice
Approvals — FDA: no, EMA: no, PMDA: no
Description: Juice supplemented with 15 μg vitamin D2
Study: 28679555
Drug: Biscuit supplemented
Approvals — FDA: no, EMA: no, PMDA: no
Description: Biscuit supplemented with 15 μg vitamin D2
Study: 21080844
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (no cell treatment)
Study: 16932286
Drug: Alendronate and
Normalized name: alendronate
DrugBank: Alendronic acid (DB00630)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Alendronate and risedronate (oral nitrogen-containing bisphosphonates)
Study: 9550632
Drug: NG‐monomethyl‐L‐arginine (L‐NMMA,
Approvals — FDA: no, EMA: no, PMDA: no
Description: NG‐monomethyl‐L‐arginine (L‐NMMA, 3 mg/kg priming dose plus 3 mg/kg/h) for 3 hours
Study: 3276343
Drug: Amoxicillin-clavulanate (Augmentin)
Normalized name: amoxicillin / clavulanate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amoxicillin-clavulanate (Augmentin)
Study: 29032666
Drug: Fimasartan 30
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fimasartan 30 mg
Study: 25850881
Drug: Fimasartan 30
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fimasartan 30 mg/Amlodipine 5 mg
Study: 25850881
Drug: Fimasartan 30
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fimasartan 30 mg/Amlodipine 10 mg
Study: 25850881
Drug: Fimasartan 60
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fimasartan 60 mg/Amlodipine 5 mg
Study: 21242819
Drug: EPT (50
Approvals — FDA: no, EMA: no, PMDA: no
Description: EPT (50 μg transdermal estradiol daily and 200 mg/d micronized progesterone for the first 14 days of each month; n = 21)
Study: 21242819
Drug: Raloxifene (60
Approvals — FDA: no, EMA: no, PMDA: no
Description: Raloxifene (60 mg daily; n = 17)
Study: 21242819
Drug: Control (no
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control (no treatment; n = 21)
Study: 9343463
Drug: EGb (120
Approvals — FDA: no, EMA: no, PMDA: no
Description: EGb (120 mg/d)
Study: 3024689
Drug: Triprolidine 10
Normalized name: phenylephrine HCl/triprolidine 10 mg-2.5 mg ORAL TABLET
Approvals — FDA: no, EMA: no, PMDA: no
Description: Triprolidine 10 mg (active control)
Study: 27261562
Drug: Clinician-guided Cognitive
Normalized name: DuoCare Clinical
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clinician-guided Cognitive Behaviour Therapy (CG‐CBT)
Study: 27261562
Drug: Self-guided Cognitive
Approvals — FDA: no, EMA: no, PMDA: no
Description: Self-guided Cognitive Behaviour Therapy (SG‐CBT)
Study: 25173752
Drug: GLP-2 administration
Normalized name: (Gly2)GLP-2
Approvals — FDA: no, EMA: no, PMDA: no
Description: GLP-2 administration
Study: 25173752
Drug: GLP-2 administration
Normalized name: (Gly2)GLP-2
Approvals — FDA: no, EMA: no, PMDA: no
Description: GLP-2 administration 7 hours after a high-fat meal
Study: 20685494
Drug: Buprenorphine transdermal
Normalized name: Buprenorphine Transdermal System
DrugBank: Buprenorphine (DB00921)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Buprenorphine transdermal system (BTDS) 10 to 40 microg/h
Study: 18435869
Drug: Standard psychiatric
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard psychiatric out-patient treatment (Control)
Study: 15939681
Drug: GIK solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: GIK solution (300 g glucose + 50 IU crystallized insulin + 80 mEq potassium chloride in one liter solution)
Study: 6137856
Drug: Alprazolam 1.5-3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alprazolam 1.5-3 mg per day
Study: 6137856
Drug: Diazepam 15-30
Normalized name: diazepam 15 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diazepam 15-30 mg per day
Study: 31863809
Drug: Surface treatment
Normalized name: hepatitis B surface antigen vaccine Injection [Recombivax]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Surface treatment
Study: 31863809
Drug: CFU/mL
Normalized name: mumps skin test antigen 40 CFU/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: CFU/mL
Study: 17430323
Drug: Saline 0.9%,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Saline 0.9%, 2 ml
Study: 1328366
Drug: Dietary treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dietary treatment based on weight reduction and sodium restriction
Study: 23156846
Drug: 0.1% tacrolimus
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.1% tacrolimus (FK‐506) eye ointment
Study: 19167587
Drug: Rosiglitazone hydrochloride
DrugBank: Rosiglitazone (DB00412)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Rosiglitazone hydrochloride (test formulation)
Study: 14508308
Drug: 0.2 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.2 mg/kg intravenous M6G
Study: 14508308
Drug: 0.13 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.13 mg/kg intravenous morphine
Study: 8973852
Drug: Chemotherapy after
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chemotherapy after the first trimester of pregnancy
Study: 1866057
Drug: A‐HDF (1.75
Approvals — FDA: no, EMA: no, PMDA: no
Description: A‐HDF (1.75 mmol/l calcium)